Hyperpolarised 13C-Pyruvate MRI Study
NCT03687645 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2018-09-27
Summary
Metabolic changes related to disease are the precursor to anatomical changes in tissues. Currently the imaging methods routinely used in clinical practice look at the anatomical changes. Whilst these methods are very helpful in making clinical decisions, they are far from being perfect. Early disease can be missed because these methods are not sensitive enough and it is not clear whether disease is present or not. Additionally, it is also difficult to know whether disease it aggressive or non-aggressive.
Hyperpolarised MRI is a new imaging tool that may allow addressing these deficiencies in current imaging technology. The process of hyperpolarisation allows the production of an injectable solution that can produce signal on a standard MRI scanner inferring information about the metabolism occurring at a particular location. This technology has only just become available for clinical use.
The initial stages of evaluation require the investigators to refine and develop the new imaging protocols so that assessment can be made as to whether consistent results can be achieved. Additionally, refining the imaging protocol could also aid in identifying where the best potential future clinical use of this technology should be targeted.
Within this application the investigators aim to try out hyperpolarised MRI in a number of different cancers and also see whether it is useful to assess cardiac metabolism. The investigators will be using 13C-labelled metabolites (for this study 13C- pyruvate) which will allow interrogation of glucose metabolism. The derangement of glucose metabolism is common to a number of disease processes.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Hyperpolarised MRI
Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
Sponsors & Collaborators
- collaborator OTHER
-
University College, London
lead OTHER
Principal Investigators
-
Dr Shonit Punwani · University College, London
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-01
- Primary Completion
- 2020-06-30
- Completion
- 2020-06-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
NCT02421380 ·Status: RECRUITING ·Phase: NA
-
Hyperpolarized 13C MRI for Cancer Immunotherapy
NCT05805358 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Quantitative MR Imaging in Locally Advanced Cervical Cancer
NCT03210428 ·Status: UNKNOWN
-
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
NCT01974804 ·Status: COMPLETED
-
FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer
NCT02995902 ·Status: COMPLETED ·Phase: NA
-
Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases
NCT04890028 ·Status: COMPLETED ·Phase: NA
-
Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.
NCT00184288 ·Status: WITHDRAWN
-
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
NCT05396118 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Characterization of Brain Metastases
NCT00184275 ·Status: COMPLETED
-
Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma
NCT01836484 ·Status: COMPLETED
-
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
NCT01741597 ·Status: WITHDRAWN ·Phase: PHASE1
-
Imaging Correlates of Renal Cell Carcinoma Biological Features
NCT01665703 ·Status: COMPLETED ·Phase: NA
-
Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer
NCT01983371 ·Status: WITHDRAWN ·Phase: NA
-
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
NCT00842790 ·Status: COMPLETED
-
Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques
NCT06016075 ·Status: RECRUITING ·Phase: NA
-
Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer
NCT03469726 ·Status: UNKNOWN ·Phase: NA
-
A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion
NCT01210027 ·Status: COMPLETED
-
Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study
NCT05202015 ·Status: UNKNOWN
-
Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers
NCT02966574 ·Status: UNKNOWN ·Phase: NA
-
MRI in Diagnosing Solid Tumors of the Eye and Orbit
NCT01653080 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Early Versus Late FDG-PET/CT in Bladder Cancer
NCT03065725 ·Status: COMPLETED
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
NCT03680144 ·Status: COMPLETED ·Phase: NA
-
Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA
NCT04807582 ·Status: COMPLETED
-
Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation
NCT03839706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA